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Abstract
The National Institute on Aging in conjunction with the Alzheimer’s Association (NIAAA) recently proposed a biological framework for defining the Alzheimer’s disease
(AD) continuum. This new framework is based upon the key AD biomarkers (amyloid, tau, neurodegeneration, AT[N]) instead of clinical symptoms and represents the
latest understanding that the pathological processes underlying AD begin decades
before the manifestation of symptoms. By using these same biomarkers, individuals
with Down syndrome (DS), who are genetically predisposed to developing AD, can also
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be placed more precisely along the AD continuum. The A/T(N) framework is therefore thought to provide an objective manner by which to select and enrich samples for
clinical trials. This new framework is highly flexible and allows the addition of newly
confirmed AD biomarkers into the existing AT(N) groups. As biomarkers for other
pathological processes are validated, they can also be added to the AT(N) classification
scheme, which will allow for better characterization and staging of AD in DS. These
biological classifications can then be merged with clinical staging for an examination
of factors that impact the biological and clinical progression of the disease. Here, we
leverage previously published guidelines for the AT(N) framework to generate such a
plan for AD among adults with DS.
KEYWORDS

Alzheimer’s disease, biomarkers, Down syndrome

1

INTRODUCTION

In 2013, the Food and Drug Administration (FDA) released draft
guidance on drug development for AD. The guidance built on the under-

A core purpose for the generation of the amyloid, tau, neurodegeneration (AT[N]) framework was to “enable a more precise approach to
interventional trials where specific pathways can be targeted in the disease progress and in the appropriate people.”1 Recently, the National
Institute on Aging and Alzheimer’s Association (NIA-AA) proposed a
“research framework” based on the AT(N) model2 for observational
and interventional research on Alzheimer’s disease (AD).3 Differently
from the prior NIA-AA diagnostic criteria,4 this framework defines AD
as a biological rather than a clinical construct, characterized by extracellular deposits of amyloid-beta peptide (Aβ; “A”), intraneuronal aggregates of hyperphosphorylated tau (“T”) and neurodegeneration (“[N]”).

standing that AD is a progressive disease with clinical symptoms of
dementia appearing decades after the AD pathophysiological process
has begun and proposed a disease classification that acknowledged
three stages of AD: the preclinical, prodromal, and dementia stages.8
In 2018, the FDA revised the draft guidance and expanded the taxonomy of AD by recognizing four stages.9 These include: Stage 1: “Preclinical AD”; Stage 2: “Preclinical/ Prodromal AD”; Stage 3: “Prodromal
AD”; and Stage 4: “AD dementia.” We are now poised to study these
stages of AD in Down syndrome (DSAD) using the most advanced AD
biomarkers available to refine the AT(N) classification for use in this
population.

The “N” is placed in parentheses to emphasize that the biomarkers in
the (N) group are fundamentally different from “A” and “T” biomarkers because they are: (1) not specific for neurodegeneration due to AD,
(2) may be attributed to other possible comorbid conditions, and (3)

2
APPLICATION OF AT(N) TO THE DS
POPULATION

do not map onto neuropathologic findings used to diagnose AD. The
AT(N) model considers A, T, and (N) status relatively independent from

To date, the AT(N) framework has been applied in limited ways to

one another with a known sequential order. However, the model then

other populations that are at risk for AD as a method to expand this

combines the clinically defined diagnostic classifications with AT(N)

model and to enrich clinical trials for AD.10 Given the unique features

biomarker status for consistent terminology for research use.

described below of AD among adults with DS, the framework may have

Briefly, negative amyloid and tau along with the absence of neu-

utility for rapid advancement of precision medicine approaches to

rodegeneration (A−T−[N]–) defines the normal biomarker profile,

novel clinical trials in this population. DS is, by definition, a genetically

and amyloid negativity with either positivity for tau or presence of

determined form of AD as recognized in the International Work Group

neurodegeneration corresponds to suspected non-Alzheimer’s pathol-

on Criteria for AD (IWG-2).11 In DS, one of the most common forms

ogy. β-Amyloidosis (A+) is sufficient to identify the Alzheimer’s

of intellectual disability, the underlying genetic link between trisomy

continuum. Within this continuum, A+T−(N)– denotes Alzheimer’s

21 and AD has been convincingly established.12-15 By age 40 years,

pathologic change (preclinical AD), while A+T+ (with or without [N]+)

all adults with DS exhibit some degree of elevated brain amyloid.16-18

establishes definite AD. The AT(N) framework has the potential to

The leading explanation for this link is tied to the triplication of

enrich clinical trials with individuals who show objective evidence that

chromosome 21 (trisomy 21) and the resulting overexpression of the

they are on the AD continuum while also permitting the staging of

amyloid precursor protein (APP) gene coded on this chromosome.19

individual patients and providing prognosis as well as stratification for

The excessive production of Aβ as a result is key to the pathogenesis

precision-based clinical trials. The AT(N) classification system has been

of AD in adults with DS.20 Although other genes coded on chromo-

studied by multiple groups and has demonstrated utility in classifying

some 21 may contribute to the early emergence of dementia and the

individuals with late-onset sporadic AD on the basis of biomarkers.5-7

phenomenon of accelerated aging seen in adults with DS,21 forms
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of partial trisomy 21 which do not result in triplication of APP (ie,
the APP-containing portion of chromosome 21 is not present in the

RESEARCH IN CONTEXT

third copy) are not associated with clinical and pathological signs of
1. Systematic review: Alzheimer’s disease (AD) is highly

AD.14,15
Despite these consistent AD neuropathologic changes, the timing of
the development of dementia as part of AD in DS is quite variable,22
suggesting the presence of other genetic and environmental risk and
protective factors. Individuals with DS have a lifetime risk for dementia in excess of 90%, and DS is now acknowledged to be a genetic form
of AD similar to the much less common autosomal-dominant causes of
AD.23,24 Although the development of dementia is not inevitable in all
adults with DS, the risk increases incrementally with

age.25

Further-

more, as in the late-onset form in the general population, the AT(N)
classification of adults with DS will be strongly influenced by the age

prevalent in Down syndrome (DS). The National Institute
on Aging in conjunction with the Alzheimer’s Association (NIA-AA) recently proposed a biological framework
for defining the AD continuum. This new framework is
based on key AD biomarkers (amyloid, tau, neurodegeneration, AT[N]) instead of clinical symptoms and represents the latest understanding that the pathological processes underlying AD begin decades before the manifestation of symptoms.
2. Interpretation: These biological classifications can then
be merged with clinical staging for an examination of fac-

of the individual.
Identifying cognitive impairment at an early stage of the AD continuum has become an increasingly important goal in AD research, as
it is widely believed that the greatest chance for therapeutic success
will be obtained by intervening early in the disease, before widespread
and irreversible neurodegeneration has

occurred.26

As a result, the

AT(N) framework describes AD across its full spectrum (ie, preclinical
to dementia) in terms of biomarker positivity/negativity and is agnostic with respect to clinical symptoms. As more longitudinal data are
collected in DS, correlations between the distinct AT(N) classifications
with clinical and cognitive status will be possible as well as a richer

tors that impact the biological and clinical progression of
the disease. We leverage previously published guidelines
for the AT(N) framework to generate such a plan for AD
among adults with DS.
3. Future directions: Further work on longitudinal AD
biomarkers in DS should help clarify whether the AT(N)
classification system can be applied to individuals with DS
both for clinical trial stratification as well as for use as a
potential staging and prognostic tool in the clinic, representing a fundamental tool for precision medicine.

understanding of the rates of change in each biomarker category: amyloid, tau, and neurodegeneration across the AD conitnuum in DS. This
more precise assessment will facilitate primary, secondary, and tertiary
prevention trials for ADin individuals with DS.27-29
In the general population30-32 as well as in DS33-36 the construct

3
CLINICAL ASSESSMENT OF COGNITIVE
STATUS

of mild cognitive impairment (ie, prodromal AD) as well as the identification of disease in the preclinical stage (eg, accumulation of

The defining feature of all causes of dementia is a decline from the

amyloid in a cognitively stable individual) is central to the clinical diag-

baseline level of function and performance of daily skills. Although this

nostic formulation of AD. Mild cognitive impairment (MCI) in the gen-

may be straightforward to establish in the general population, it can

eral population, as well as in DS, is generally regarded as the border-

be a much more complicated task in adults with DS because of life-

land between the cognitive changes of aging and early dementia where

long intellectual impairment and significant variance in baseline cog-

there is measurable decline in memory as well as some decline on

nitive functioning.45,46 This is especially true for older adults with DS

instrumental activities of daily living (iADLs) but preservation of basic

due to various factors impacting living arrangements in which there

activities of daily functioning.22,37-40 The characterization of preclini-

may be poor record keeping since childhood, lack of continuity in staff

cal and prodromal AD is now possible with the advancement of state-

members supervising adults with DS over time, and a large number

of-the-art biomarker modalities such as amyloid and tau assessment

of physicians/health-care providers throughout his or her life span.

using positron emission tomography (PET) imaging and cerebrospinal

In the absence of a personal historian who can accurately and com-

fluid (CSF) measures as well as emerging plasma biomarkers such as

prehensively attest to an individual’s baseline level of functioning, the

mass spectral Aβ

assays41,42

in the absence of or minimal cognitive

decline.

assessment of a reported cognitive and behavioral change may be
exponentially more difficult.47,48 The early signs of dementia in adults

Here we propose an application of the AT(N) framework for the full

with DS can be subtle and often require an astute observer to iden-

characterization of the AD continuum in DS using both state-of-the-art

tify these changes. Often, individuals with DS are served by numerous

biomarkers and clinical assessments. Given the variability in cognitive

caregivers throughout their lifetime, and often newly involved care-

assessments, the inclusion of biomarkers may facilitate the evaluation

givers will presume that the current level of observed ability repre-

of potential efficacy of therapy in this population. Forthcoming data

sents the individual’s baseline level of functioning and, thus, miss signs

from the Alzheimer’s Biomarker Consortium–Down Syndrome (ABC-

of early decline that has already occurred.

DS)43 and the European Horizon21 consortium44 will inform the diagnostic accuracy and prognostic potential of AT(N) in DS.

In the clinical setting, accurate assessment of cognition and function
depend upon a comprehensive history, which for individuals with DS

4 of 10

RAFII ET AL .

must be done in the context of knowledge and quantification of their

MRI, as well as biofluid markers in CSF and plasma.59 There exist

historic level of intellectual disability.49

It is important that a thorough

remarkable similarities between AD biomarkers in DS and other popu-

history be obtained to compile evidence consistent with an emerging

lations with AD.60-64 Greater hippocampal atrophy is associated with a

cognitive impairment while probing for potential factors contributing

greater amyloid load.61 Cognitive and functional measures do not cor-

to decline. Pertinent historical information is useful from personal

relate as strongly with amyloid deposition as they do with abnormali-

accounts of caregivers and family members who have known the

ties on 18F-fluourodeoxyglucose (FDG) and tau PET.61,65,66

individual for an extended length of

time.50

In addition, other sources

of information, such as previous neuropsychological testing or school
Individual Education Plan information, can greatly assist in accurately

4.1

Amyloid (A)

characterizing an individual’s baseline level of functioning. In addition,
medical history, medications, family history, social history, review of

Amyloid PET positivity as observed using PET imaging in DS seems

systems, laboratory evaluations, and brain imaging will be essential to

to resemble autosomal dominant AD more closely than sporadic AD.

rule out comorbidities that can masquerade as AD-related cognitive

Specifically, Pittsburgh compound B (PIB) demonstrates an early and

impairment. Objective evidence of memory decline will be essential

predominant basal ganglia signal60,62,67,68

for the diagnosis of MCI-DS and dementia. A number of cognitive

although other tracers (eg, florbetabir) have shown a pattern more

assessment instruments are currently being evaluated in natural

similar to sporadic AD.61 The similarity of AD in DS and ADAD is

history studies of AD in DS, including the ABC–DS.43 At this time,

thought to result from overproduction of Aβ. APP overproduction in DS

there is no single cognitive instrument that has been longitudinally

leads to baseline plasma levels of Aβ40 and Aβ42 and Aβ42/Aβ40 ratios

validated in the context of AD biomarkers in DS but many are being

which are higher than those in non-DS individuals.64,69,70 A positive

presently intensely researched.51-55

correlation of tau and a negative correlation of CSF Aβ1-42 have been

Once arriving at the suspected clinical diagnosis of MCI or dementia,

reported with age71 and several studies have documented correlations

the AT(N) framework can be used to stage an individual with DS along

of the changes in amyloid in DS with AD.72-75 Higher levels of Aβ42

the AD continuum with respect to extent of underlying biomarker

or the Aβ42/Aβ40 ratio appear to be associated with the onset of AD

changes (Table 1). This staging can be used to provide expected clinical

in DS,76,77 although this is not entirely consistent in the literature.78

prognosis, including an estimated duration of independent functioning,

CSF Aβ42 levels are first increased in early life and then become lower

time to dementia, and to also enrich for more homogenous samples in

with age, representing deposition of Aβ into plaques.64,79,80 Most stud-

clinical trials. The proposed clinical staging of the cognitive continuum

ies seem to suggest that as with sporadic and autosomal-dominant AD,

was adapted from previously published guidelines for preclinical AD,56

pathophysiological changes associated with AD in DS occur approxi-

MCI,57 and AD dementia.58

mately two decades before the onset of symptoms of dementia.

The difficulties with MCI diagnoses in the general population are

Blood-based biomarkers have clear advantages as biomarkers as

well established. MCI in adults with DS (MCI-DS) is an even more

they are easily accessible. Individuals with DS have higher baseline

challenging diagnosis and cross-sectional assessments can be unreli-

plasma Aβ1-42 and Aβ1-40 concentrations compared to individuals

able. Therefore, longitudinal assessments are optimal and required.

without DS81 due to the extra copy of the APP gene and the result-

Additional work is needed to determine optimal psychometric assess-

ing overproduction of APP and Aβ. There have been a limited num-

ment instruments, cutoff scores, and/or combinations of instruments

ber of CSF studies in individuals with DS which show elevated levels

in this population for refinement of the MCI designation. Specifically,

of Aβ42 early in life, but with age, CSF Aβ42 levels decline (as expected

the following points will need to be considered as the concept of MCI-

with their deposition into plaques) while CSF tau levels progressively

DS evolves and will be informed by forthcoming data from ABC–DS:

increase.64,81

(1) Identification of the most informative cognitive assessment instruments for MCI varying based on severity of ID. (2) Quantification of
decline needed to represent a clinically meaningful change. (3) Rela-

4.2

Tau (T)

tionship between cognitive assessments and rates of change in various
AD biomarkers. In order to confirm that MCI-DS is in fact prodromal

Neurofibrillary tangles (NFTs)which are comprised of abnormal tau,

AD, the use of biomarkers to confirm AD as the underlying etiology will

are a key pathological hallmark of AD and correlate with the emer-

be required.

gence of clinical symptoms more closely than amyloid plaques. This
relationship has also been demonstrated in post mortem pathology of
DS brains, where NFTs correlate with cognitive decline.82 Tau PET sig-

4
BIOMARKER ASSESSMENTS OF AMYLOID,
TAU, AND NEURODEGENERATION IN DS

nal in the DS brain appears to be similar to sporadic AD and can be
assessed using standard Braak staging.66 Specifically, tau deposition in
adults with DS has been studied using the PET tracer (18 F) AV-1451.66

Over the past few years, substantial progress has been made in elu-

Abnormal tau distribution (in the form of NFTs) first involves the medial

cidating the natural history of AD in people with DS using the latest

temporal cortices and then spreads posteriorly,66 similar in manner to

biomarkers including amyloid and tau PET imaging, volumetric brain

that observed in sporadic AD. More recently, plasma and CSF tau have
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TA B L E 1

Clinical staging of cognitive continuum—Diagnostic recommendations

Cognitively Stable (Preclinical Alzheimer’s Disease)
1. No report of cognitive decline that is greater than what would be expected with aging, based on informant or clinician report—subjective decline
taken into account, but not a requirement
2. No objective evidence of cognitive decline that is greater than what would be expected with aging per se on formal neuropsychological testing
(brief cognitive screening instruments are insufficient with this population)
a. If first assessment, impairment is defined compared to estimated premorbid level of functioning (eg, functional measure, IQ measure)
(i) Confidence of diagnosis is less
b. If prior testing is available, impairment is defined based on decline from prior testing levels
(i) Confidence of diagnosis is high
3. Preservation of premorbid level of functional abilities based on reliable informant report, unless functional decline is related to age-associated
frailty unrelated to AD (ie, muscle weakness, etc.).
Mild Cognitive Impairment–Down Syndrome (Prodromal AD)
1. Report of decline in cognitive functioning as reported by reliable informant or clinician AND
2. Objective evidence of impairment in one or more cognitive domains, based on extensive neurocognitive testing (brief cognitive screening
instruments are insufficient with this population)
a. Cognitive impairment may be in any of the following domains:
(i) Impaired ability to acquire and remember new information
(ii) Impaired reasoning and handling of complex tasks from premorbid level
(iii) Impaired visuospatial abilities
(iv) Impaired language functions
(v) Changes in personality, behavior, or other neuropsychiatric symptoms that may include uncharacteristic fluctuations in mood (eg,
agitation), depression, changes in motivation, apathy, social withdrawal, loss of interest in previous activities, among others
b. If first assessment, impairment is defined as compared to estimated premorbid level of functioning (eg, functional measure, IQ measure)
(i) Confidence of diagnosis is lower
c. If prior cognitive testing is available, impairment is defined based on decline from prior testing levels
3. Confidence of diagnosis is high
4. Cognitive changes are not better explained by other factors such as significant life event (eg, environmental change, medical illness, etc.)
5. Preservation of premorbid level of basic functional abilities (basic ADLs) based on reliable informant report. There may be declines in iADLs in
the DS population
Dementia in Down Syndrome
1. Cognitive concern reflecting a change as reported by reliable informant or clinician report–subjective decline taken into account if present, but
not a requirement
2. Objective evidence of impairment in two or more cognitive domains, based on formal neurocognitive testing (brief cognitive screening
instruments are insufficient with this population)
a. Cognitive impairment may be in any of the following domains:
(i) Impaired ability to acquire and remember new information
(ii) Impaired reasoning and handling of complex tasks from premorbid level
(iii) Impaired visuospatial abilities
(iv) Impaired language functions
(v) Changes in personality, behavior, or other neuropsychiatric symptoms that may include: uncharacteristic fluctuations in mood (eg,
agitation), changes in motivation, apathy, social withdrawal, loss of interest in previous activities, among others
b. If first assessment, impairment is defined as compared to estimated premorbid level of functioning
(i) Confidence of diagnosis is less
c. If prior testing is available, impairment is defined based on decline from prior testing levels
(i) Confidence of diagnosis is high
3. Cognitive changes are not better explained by other factors such as significant life event (eg, environmental change), or active medical or mental
illness, etc.
4. Changes in cognition and/or neuropsychiatric/behavioral symptoms interfere with previous level of daily functioning (basic ADLs) based on
informant and/or clinician report – subjective decline taken into account but not a requirement.
Abbreviations: AD, Alzheimer’s disease; ADL, activities of daily living; DS, Down syndrome; iADL, instrumental activities of daily living.

been studied in individuals with DS, with their levels correlating with

autosomal dominant forms of AD. More recently, plasma neurofil-

AD dementia in DS.64,78,83-85

ament light chain (NfL) levels (also a marker of neurodegeneration)
have been shown to correlate with clinical status of AD in DS92 as
well as standard AD biomarkers such as amyloid PET and tau PET.93

4.3

Neurodegeneration (N)

Specifically, plasma NfL levels appear to increase with age in but can
still distinguish between normal aging and AD81,92 . Plasma NfL levels

Markers

regional

have also been shown to correlate with other markers of neurode-

hypometabolism on FDG PET986-88 or hippocampal atrophy89-91

of

AD-specific

neurodegeneration

include

generation such as hypometabolism on FDG PET and hippocampal

have been studied in DS and parallel findings from the sporadic and

atrophy, as well as cognitive and functional decline.93
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Biomarker classification AT(N) pathology among adults

elevated tau or any neurodegeneration (A+/T−/N−) would be categorized as preclinical AD. An individual who has symptoms consistent
with MCI-DS who has elevated brain amyloid but no elevated tau or

**Biomarker classification is independent of Consensus Clinical
Staging of Cognitive Continuum
AT(N) Biomarker Grouping
A: Aggregated Aβ or associated pathophysiologic state
CSF Aβ42 , or Aβ42 /Aβ40 ratio
Amyloid PET
T: Aggregated tau (neurofibrillary tangles) or associated
pathophysiologic state
CSF phosphorylated tau
Tau PET
(N): Neurodegeneration or neuronal injury
Anatomic MRI
FDG PET
CSF total tau

evidence of neurodegeneration (A+/T+/N) would be classified as Prodromal AD. Finally, an individual with MCI-DS but who is A−/T+/N−
would be considered as having a neurodegenerative disease other
than AD (non-AD) as the basis for their symptoms. Therefore, by use of
the A/T(N) framework, it is anticipated that we will be able to conduct
clinical trials in a more finely characterized participant sample.

5

ESTIMATING A+/T+(N)+ PREVALENCE IN DS

We intend to look at AT(N) classification across the different clin-

Abbreviations: Aβ, amyloid beta; AT(N), amyloid, tau, neurodegeneration;
CSF, cerebrospinal fluid; FDG, 18F-fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography

ical diagnostic categories, that is, Cognitively Stable, Mild Cognitive Impairment, and Dementia in the ABC-DS Study to calculate
A+/T+/(N)+ prevalence and to correlate the various classifications with clinical and cognitive status. Based on a review of the

Thus, various biomarker modalities (eg, imaging, biofluids) can be

literature,20,36,41,42,59-93 we estimate that, between ages 35 to 55

used to characterize individuals with DS as exhibiting amyloid, tau, or

years, there will be 80% A+, 40% T+, and 10% (N)+ for cognitively

neurodegeneration “positivity” in the AT(N) classification scheme. The

stable adults with DS; 80% A+, 60% T+, and 20% (N)+ for MCI-DS;

biomarkers currently being used to characterize individuals with DS

and 80% A+, 80% T+, and 60% (N)+ for dementia in the DS group

are listed in Table 2.

(Figure 1).

The AT(N) classification scheme can then be applied to such individ-

There may be limitations specific to the A/T(N) classification sys-

uals as depicted in Table 3. Briefly, individuals with DS with stable cog-

tem. For example, amyloid imaging may underestimate true amy-

nition who have no elevations in brain amyloid or tau and no evidence

loid positivity. In addition, some biomarkers indicating tau pathol-

of neurodegeneration would be classified as A−/T−/N−. Therefore,

ogy may become positive at different stages of the disease (ie, CSF

they would not be on the AD continuum. However, an individual with

becoming abnormal before PET imaging). And, there appears to be a

stable cognition who has elevated brain amyloid but no evidence of

potential discrepancy between timing of positive MRI indicators of

TA B L E 3

AT(N) Framework for adults with Down syndrome
Combined syndromal cognitive and biomarker categorization

AT(N) profiles

Biomarker category

Part of
Alzheimer’s
continuum (Y/N)

A-/T−/(N)−

Normal biomarkers

A+/T−/(N)−
A+/T+/(N)−

Stable cognition

MCI

Dementia

No

Stable cognition +
normal AD biomarkers

MCI-DS + normal AD
biomarkers

Dementia + normal AD
biomarkers

AD pathological change

Yes

Preclinical AD
pathological change

MCI-DS + AD
pathological change

Dementia + AD
pathological change

AD

Yes

Preclinical AD

Prodromal AD

AD + dementia

A+/T+/(N)+

AD

Yes

Preclinical AD

Prodromal AD

AD + dementia

A+/T−/(N)+

AD and concomitant
suspected non- AD
pathological change

Yes

Preclinical AD*

Prodromal AD*

AD* + dementia

A−/T+/(N)−

Non-AD pathological
Change

No

Preclinical non-AD

MCI not due to AD

Non-AD dementia

A−/T−/(N)+

Non-AD pathological
Change

No

Preclinical non-AD

MCI not due to AD

Non-AD dementia

A−/T+/(N)+

Non-AD pathological
Change

No

Preclinical non-AD

MCI not due to AD

Non-AD dementia

NOTE: AD* = AD and concomitant suspected non-AD pathological changes
Abbreviations: AT(N), amyloid, tau, neurodegeneration; AD, Alzheimer’s disease; MCI, mild cognitive impairment.
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F I G U R E 1 Estimated prevalence of A/T(N) positivity across clinical diagnoses. We estimate that between ages 35 to 55 years, there will be
80% A+, 40% T+, and 10% (N)+ for cognitively stable adults with Down syndrome (DS); 80% A+, 60% T+, and 20% (N)+ for mild cognitive
impairment (MCI)-DS; and 80% A+, 80% T+, and 60% (N)+ for the dementia in DS group. A+ = elevated brain amyloid, T+ = tau pathology
present, (N) = neurodegeneration present

atrophy (and hence neurodegeneration) versus increased levels of

and to facilitate a better understanding of the biology ofAD in adults

plasma NfL. Finally, these differences indicate that dichotomization

with DS. This research framework is not intended for clinical use at this

may potentially decrease sensitivity to changes in cognition.

time.

As longitudinal data become available, the utility of the AT(N)

Further work on longitudinal AD biomarkers in DS should help clar-

classification scheme will be compared with each individual’s clinical

ify whether the AT(N) classification system can be applied to individ-

status over time. We will test if there are differences between the

uals with DS both for clinical trial stratification as well as for use as a

biochemical and neuroimaging measures of AT(N) . We will confirm

potential staging and prognostic tool in the clinic, representing a fun-

prevalence of AD biomarker positivity across different ages and clini-

damental tool for precision medicine.

cal diagnoses. Additionally, we will assess how best we can operationalize the biomarker binarization to ensure the external validity of the
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CONCLUSIONS

Recent work on the AT(N) frameworkin the general population suggests that individuals exhibiting abnormalities on all three biomarkers
are at the greatest risk of developing AD dementia. The AT(N) model
considers A, T, and (N) status relatively independent from one another
with a known sequential order. The current framework is proposed as
a starting point for use of A/T(N) classificationin the DS population. It
is understood that this is not a final model and as new data emerge, the
framework will be revised and updated accordingly in order to parallel
the state of current knowledge. As with the original AT(N) Framework,
this staging system is intended to aid in the refinement of clinical trials
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